Adherence to Drugs That Prevent Cardiovascular Disease: Meta-analysis on 376,162 Patients

Naderi, Hafiz; Bestwick, Jonathan P.; Wald, David S

doi:10.1016/j.amjmed.2011.12.013

Cited by 680 publications

(535 citation statements)

References 38 publications

Supporting

Mentioning

425

Contrasting

Unclassified

Order By: Relevance

“…457 -461 Poor adherence rates are not only limited to statins but are also true of other lipid-lowering drugs and all medications used to prevent CVD, as demonstrated in a systematic review and meta-analysis. 462 The reasons for non-adherence are complex and include misconceptions about tolerability on the part of both patients and professionals alike. These barriers prevent patients from gaining the maximum benefit from their treatment.…”

Section: Adhering To Medicationsmentioning

confidence: 99%

ESC/EAS Guidelines for the management of dyslipidaemias

Catapano¹,

Reiner²,

Backer³

et al. 2011

Atherosclerosis

565

189

View full text Add to dashboard Cite

Section: Adhering To Medicationsmentioning

confidence: 99%

ESC/EAS Guidelines for the management of dyslipidaemias

Catapano¹,

Reiner²,

Backer³

et al. 2011

Atherosclerosis

565

189

View full text Add to dashboard Cite

“…Adherence seems to be an area where lots can be achieved [4]. It is a big issue not only in treating HT, but also in lipid lowering therapy and aspirin in both primary and secondary prevention [10]. The problem often begins right after leaving the doctor's office.…”

Section: Discussionmentioning

confidence: 99%

Seasonal trends in hypertension in Poland: evidence from Google search engine query data

et al. 2018

View full text Add to dashboard Cite

A b s t r a c tBackground: Various conditions, including arterial hypertension, exhibit seasonal trends in their occurrence and magnitude. Those trends correspond to an interest exhibited in the number of Internet searches for the specific conditions per month. Aim:The aim of the study was to show seasonal trends in the hypertension prevalence in Poland relate to the data from the Google Trends tool. Methods:Internet search engine query data were retrieved from Google Trends from January 2008 to November 2017. Data were calculated as a monthly normalised search volume from the nine-year period. Data was presented for specific geographic regions, including Poland, the United States of America, Australia, and worldwide for the following search terms: "arterial hypertension (pol. nadciśnienie tętnicze)", "hypertension (pol. nadciśnienie)" and "hypertension medical condition". Seasonal effects were calculated using regression models and presented graphically.

show abstract

“…13,23 Conversely, if the true effect of aspirin is much smaller than estimated by Rothwell and colleagues (as suggested by Seshasai and colleagues, who estimated a relative risk of 0.93), 9 then there will be few or no effects on the threshold for net benefit from the mortality effect alone. Our analysis assumed full adherence to aspirin, so as to answer the question of what the effect of regular use would be; however, adherence to preventive medicines is sub-optimal, 29 and we have not included the costs of systematic adherence promotion, so its actual beneficial effects when offered to a population will be smaller (as will its adverse effects).…”

Section: Discussionmentioning

confidence: 99%

“…[28][29][30][31][32][33][34][35][36][37][38][39] Utilities. The utilities for each health state were drawn from the literature and are also shown in Table 1.…”

Section: 22122mentioning

confidence: 99%

Effect of Including Cancer Mortality on the Cost-Effectiveness of Aspirin for Primary Prevention in Men

et al. 2013

View full text Add to dashboard Cite

BACKGROUND: Recent data suggest that aspirin may be effective for reducing cancer mortality. OBJECTIVE: To examine whether including a cancer mortality-reducing effect influences which men would benefit from aspirin for primary prevention. DESIGN: We modified our existing Markov model that examines the effects of aspirin among middle-aged men with no previous history of cardiovascular disease or diabetes. For our base case scenario of 45-year-old men, we examined costs and life-years for men taking aspirin for 10 years compared with men who were not taking aspirin over those 10 years; after 10 years, we equalized treatment and followed the cohort until death. We compared our results depending on whether or not we included a 22 % relative reduction in cancer mortality, based on a recent meta-analysis. We discounted costs and benefits at 3 % and employed a third party payer perspective. MAIN MEASURE: Cost per quality-adjusted life year (QALY) gained. KEY RESULTS: When no effect on cancer mortality was included, aspirin had a cost per QALY gained of $22,492 at 5 % 10-year coronary heart disease (CHD) risk; at 2.5 % risk or below, no treatment was favored. When we included a reduction in cancer mortality, aspirin became cost-effective for men at 2.5 % risk as well (cost per QALY, $43,342). Results were somewhat sensitive to utility of taking aspirin daily; risk of death after myocardial infarction; and effects of aspirin on stroke, myocardial infarction, and sudden death. However, aspirin remained cost-saving or cost-effective (< $50,000 per QALY) in probabilistic analyses (59 % with no cancer effect included; 96 % with cancer effect) for men at 5 % risk. CONCLUSIONS: Including an effect of aspirin on cancer mortality influences the threshold for prescribing aspirin for primary prevention in men. If such an effect is real, many middle-aged men at low cardiovascular risk would become candidates for regular aspirin use.

show abstract

Adherence to Drugs That Prevent Cardiovascular Disease: Meta-analysis on 376,162 Patients

Cited by 680 publications

References 38 publications

ESC/EAS Guidelines for the management of dyslipidaemias

ESC/EAS Guidelines for the management of dyslipidaemias

Seasonal trends in hypertension in Poland: evidence from Google search engine query data

Effect of Including Cancer Mortality on the Cost-Effectiveness of Aspirin for Primary Prevention in Men

Contact Info

Product

Resources

About